About BlueRock Therapeutics
BlueRock Therapeutics is a next-generation regenerative medicine company focused on breakthrough stem cell technology treatments of cardiovascular and neurodegenerative diseases. BlueRock Therapeutics has launched with the backing of a combined $225 million investment by Bayer and biotechnology investment firm Versant Ventures.
BlueRock’s initial programs will focus on induced pluripotent stem cell (iPSC)-derived therapeutics to expand their technology pipeline.
The firm’s strategy is to work in collaboration with leading academic and industrial partners, including the University of Toronto and the Memorial Sloan Kettering Center.
One of the programs will focus on stem-cell therapeutics for neurological diseases with high unmet need. And another is for the company to develop pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure.